CoChat

Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries

Open access
Kotzeva, Anna, Mittal, Deepali, Desai, Supriya, Judge, Davneet, Samanta, Kunal · 2023 · Journal of Medical Economics

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

Abstract

AIMS: Schizophrenia has the highest median societal cost per patient of all mental disorders. This review summarizes the different costs/cost drivers (cost components) associated with schizophrenia in 10 countries, including all cost types and stakeholder perspectives, and highlights aspects of disease associated with greatest costs. MATERIALS AND METHODS: Targeted literature review based on a search of published research from 2006 to 2021 in the United States (US), United Kingdom (UK), France, Germany, Italy, Spain, Canada, Japan, Brazil, and China. RESULTS: Sixty-four published articles (primary studies and literature reviews) were included. Comprehensive data were available on costs in schizophrenia overall, with very limited data for individual countries except the US. Most data is related to direct and not indirect costs, with extremely scarce data for several key cost components (adverse events, suicide, long-term care). Total schizophrenia-related per person per year (PPPY) costs were $2,004-94,229, with considerable variability among countries. Indirect costs were the main cost driver (50-90% of all costs), ranging from $1,852 to $62,431 PPPY. However, indirect costs are not collected systematically or incorporated in health technology assessments. Total schizophrenia-related PPPY direct costs were $4,394-31,798, with inpatient cost as the main cost driver (∼20-99% of direct costs). Intangible costs were not reported. Despite limited evidence, total schizophrenia-related costs were higher in patients with than without negative symptoms, largely due to increased costs of medication and medical visits. LIMITATIONS: As this was not a systematic review, prioritization of studies may have resulted in exclusion of potentially relevant data. All costs were converted to USD but not corrected for inflation or subjected to a gross domestic product deflator. CONCLUSIONS: Direct costs are most commonly reported in schizophrenia. The substantial underreporting of indirect and intangible costs undervalues the true economic burden of schizophrenia from a payer, patient, and societal perspective.

Overview

Integrity signals

Registry

Crossref · 10.1080/13696998.2022.2157596

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 76 references

Research works printed but not linked: 3

  1. Steinert T, Krueger M, Gebhardt RP. Costs of treatment and outcome measures in schizophrenia. Eur J Psychol Assess. 1999;13:209–214.
  2. Wilson LS, Gitlin M, Lightwood J. Schizophrenia costs for newly diagnosed versus previously diagnosed patients. Am J Pharm Benefits. 2011;3(2):107–115.
  3. Esposti LD, Sangiorgi D, Ferrannini L, et al. Cost-consequences analysis of switching from oral antipsychotics to long-acting risperidone in the treatment of schizophrenia (provisional abstract). J Psychopathol. 2012;18(2):170–176.

Cited by

See all 81

Metadata

Authors
Kotzeva, A., Mittal, D., Desai, S., Judge, D., & Samanta, K.
Affiliations
  • F. Hoffmann-La Roche AG (CH)
  • Bridge Medical Consulting Ltd, Richmond, UK
  • Roche (United Kingdom) (GB)
Corresponding author
Kotzeva, Anna
Venue
Journal of Medical Economics
Published
2022-12-25
Volume
26
Issue
1
Pages
70-83
ISSN
  • 1369-6998 (ISSN-L)
  • 1941-837X
OpenAlex
W4311206227
Cited by
57
References
76
Citations by year
2026: 13 · 2025: 21 · 2024: 16 · 2023: 7
FWCI
1.89
Type
journal article
Language
en
Open access
Locations
  • Journal of Medical Economics (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
schizophrenia, economic burden, social costs, indirect costs, direct costs, hospital costs, negative symptoms, cost drivers, suicide, long-term care, adverse events, intangible costs, cross-national comparison
MeSH terms
China, Humans, Long-Term Care, Schizophrenia, Socioeconomic Factors, United States, Health Care Costs, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries. https://app.cochat.ai/papers/10.1080/13696998.2022.2157596
The paper
Kotzeva, A., Mittal, D., Desai, S., Judge, D., & Samanta, K. (2023). Socioeconomic burden of schizophrenia: a targeted literature review of types of costs and associated drivers across 10 countries. Journal of Medical Economics. https://doi.org/10.1080/13696998.2022.2157596

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.